Moderna, a biotechnology company specialising in mRNA medicines and vaccines, entered 2024 with 45 therapeutic and vaccine programmes, including nine in late-stage development. The company outlined an ambitious pipeline strategy, anticipated approximately $4 billion in product sales for 2024 and identified several clinical and regulatory milestones expected during 2024 and 2025. Moderna, Inc., a biotechnology company developing mRNA-based therapeutics and vaccines, announced its business strategy and pipeline priorities for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference. Its plans focused on advancing nine late-stage programmes, preparing for the launch...